Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Uterine Cervical Neoplasms 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Cisplatin 13Radiotherapy, Intensity-Modulated 11Radiotherapy 5Carboplatin 5Radiation 4Cetuximab 4durvalumab 3Platinum 3Nivolumab 31,2-diaminocyclohexaneplatinum II citrate 3pembrolizumab 2fludarabine phosphate 2fludarabine 2aldesleukin 2Specimen Handling 2Restraint, Physical 2Paclitaxel 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Bupropion 2Biopsy 2Acupuncture Therapy 2veliparib 1utomilumab 1sodium thiosulfate 1ficlatuzumab 1dehydroftorafur 1Varenicline 1Transcutaneous Electric Nerve Stimulation 1Tobacco Use Cessation Devices 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Oropharyngeal Neoplasms × MEDI0457 × Clear all
NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

MedImmune LLC

Phase 1/2 Completed
35 enrolled 25 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡